A San Francisco company is preparing for a significant initial public offering. Braveheart Bio, a developer of heart drugs, is poised for a major IPO. Further details about the company's plans are available from The Business Journals. The IPO is expected to be the 2nd-largest biotech IPO this year, although specific details are not provided here and can be found through the source.